Literature DB >> 23547841

Methylation of promoters of microRNAs and their host genes in myelodysplastic syndromes.

Begum Erdogan1, Amma Bosompem, Dunfa Peng, Leng Han, Emily Smith, Mija E Kennedy, Catherine E Alford, Huiyun Wu, Zhongming Zhao, Claudio A Mosse, Wael El-Rifai, Annette S Kim.   

Abstract

Myelodysplastic syndromes (MDS) are a group of hematopoietic malignancies characterized by ineffective hematopoiesis. Recently, we identified MDS-associated microRNAs (miRNAs) that are down-regulated in MDS. This study examines possible explanations for that observed down-regulation of miRNA expression in MDS. Since genomic losses are insufficient to explain the down-regulation of all our MDS-associated miRNAs, we explored other avenues. We demonstrate that these miRNAs are predominantly intragenic, and that, in many cases, they and their host genes are expressed in a similar pattern during myeloid maturation, suggesting their co-regulation. This co-regulation is further supported by the down-regulation of several of the host genes in MDS and increased methylation of the shared promoters of several miRNAs and their respective host genes. These studies identify a role of hypermethylation of miRNA promoters in the down-regulation of MDS-associated miRNAs, unifying research on miRNAs in MDS and epigenetic regulation in MDS into a common pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23547841      PMCID: PMC4120331          DOI: 10.3109/10428194.2013.790542

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  39 in total

1.  SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications.

Authors:  F Damm; F Thol; O Kosmider; S Kade; P Löffeld; F Dreyfus; A Stamatoullas-Bastard; A Tanguy-Schmidt; O Beyne-Rauzy; S de Botton; A Guerci-Bresler; G Göhring; B Schlegelberger; A Ganser; O A Bernard; M Fontenay; M Heuser
Journal:  Leukemia       Date:  2011-11-08       Impact factor: 11.528

Review 2.  Alterations in the mitochondrial regulatory pathways constituted by the nuclear co-factors PGC-1alpha or PGC-1beta and mitofusin 2 in skeletal muscle in type 2 diabetes.

Authors:  Antonio Zorzano; María Isabel Hernández-Alvarez; Manuel Palacín; Geltrude Mingrone
Journal:  Biochim Biophys Acta       Date:  2010-02-20

3.  Target site effects in the RNA interference and microRNA pathways.

Authors:  Gregor Obernosterer; Hakim Tafer; Javier Martinez
Journal:  Biochem Soc Trans       Date:  2008-12       Impact factor: 5.407

4.  Diagnostic microRNAs in myelodysplastic syndrome.

Authors:  Begum Erdogan; Crystal Facey; Julianne Qualtieri; Jason Tedesco; Elizabeth Rinker; R Benjamin Isett; John Tobias; Donald A Baldwin; James E Thompson; Martin Carroll; Annette S Kim
Journal:  Exp Hematol       Date:  2011-06-15       Impact factor: 3.084

5.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Authors:  Lewis R Silverman; David R McKenzie; Bercedis L Peterson; James F Holland; Jay T Backstrom; C L Beach; Richard A Larson
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

6.  Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.

Authors:  Hagop M Kantarjian; Susan O'Brien; Xuelin Huang; Guillermo Garcia-Manero; Farhad Ravandi; Jorge Cortes; Jianqin Shan; Jan Davisson; Carlos E Bueso-Ramos; Jean-Pierre Issa
Journal:  Cancer       Date:  2007-03-15       Impact factor: 6.860

7.  Down-regulation of the IGF-2/H19 locus during normal and malignant hematopoiesis is independent of the imprinting pattern.

Authors:  Mathewos Tessema; Florian Länger; Oliver Bock; Axel Seltsam; Kathleen Metzig; Britta Hasemeier; Hans Kreipe; Ulrich Lehmann
Journal:  Int J Oncol       Date:  2005-02       Impact factor: 5.650

8.  High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival.

Authors:  Daniel T Starczynowski; Suzanne Vercauteren; Adele Telenius; Sandy Sung; Kaoru Tohyama; Angela Brooks-Wilson; John J Spinelli; Connie J Eaves; Allen C Eaves; Douglas E Horsman; Wan L Lam; Aly Karsan
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

9.  An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.

Authors:  Domenica Ronchetti; Marta Lionetti; Laura Mosca; Luca Agnelli; Adrian Andronache; Sonia Fabris; Giorgio Lambertenghi Deliliers; Antonino Neri
Journal:  BMC Med Genomics       Date:  2008-08-13       Impact factor: 3.063

10.  Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.

Authors:  Andrea Pellagatti; Eva Hellström-Lindberg; Aristoteles Giagounidis; Janet Perry; Luca Malcovati; Matteo G Della Porta; Martin Jädersten; Sally Killick; Carrie Fidler; Mario Cazzola; James S Wainscoat; Jacqueline Boultwood
Journal:  Br J Haematol       Date:  2008-05-08       Impact factor: 6.998

View more
  3 in total

1.  miR-223 decreases cell proliferation and enhances cell apoptosis in acute myeloid leukemia via targeting FBXW7.

Authors:  Yi Xiao; Changliang Su; Taoran Deng
Journal:  Oncol Lett       Date:  2016-09-09       Impact factor: 2.967

2.  Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes.

Authors:  Yan Guo; Amma Bosompem; Sanjay Mohan; Begum Erdogan; Fei Ye; Kasey C Vickers; Quanhu Sheng; Shilin Zhao; Chung-I Li; Pei-Fang Su; Madan Jagasia; Stephen A Strickland; Elizabeth A Griffiths; Annette S Kim
Journal:  BMC Genomics       Date:  2015-09-24       Impact factor: 3.969

3.  MicroRNA-26a-5p and microRNA-23b-3p up-regulate peroxiredoxin III in acute myeloid leukemia.

Authors:  Wenjie Jiang; Jie Min; Xiaohui Sui; Yanyan Qian; Ying Liu; Zhaojian Liu; Haibin Zhou; Xi Li; Yaoqin Gong
Journal:  Leuk Lymphoma       Date:  2014-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.